- Home
- LXEH vs ANL Comparison
LXEH vs ANL Comparison
Compare LXEH & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- ANL
- Stock Information
- Founded
- LXEH 2001
- ANL 2004
- Country
- LXEH China
- ANL Cayman Islands
- Employees
- LXEH N/A
- ANL N/A
- Industry
- LXEH Other Consumer Services
- ANL
- Sector
- LXEH Real Estate
- ANL
- Exchange
- LXEH Nasdaq
- ANL Nasdaq
- Market Cap
- LXEH 55.2M
- ANL 61.8M
- IPO Year
- LXEH 2020
- ANL 2023
- Fundamental
- Price
- LXEH $2.43
- ANL $1.78
- Analyst Decision
- LXEH
- ANL Hold
- Analyst Count
- LXEH 0
- ANL 1
- Target Price
- LXEH N/A
- ANL N/A
- AVG Volume (30 Days)
- LXEH 4.3M
- ANL 9.1K
- Earning Date
- LXEH 09-26-2025
- ANL 09-30-2025
- Dividend Yield
- LXEH N/A
- ANL N/A
- EPS Growth
- LXEH N/A
- ANL N/A
- EPS
- LXEH N/A
- ANL N/A
- Revenue
- LXEH $4,493,795.00
- ANL N/A
- Revenue This Year
- LXEH N/A
- ANL N/A
- Revenue Next Year
- LXEH N/A
- ANL N/A
- P/E Ratio
- LXEH N/A
- ANL N/A
- Revenue Growth
- LXEH N/A
- ANL N/A
- 52 Week Low
- LXEH $1.12
- ANL $1.10
- 52 Week High
- LXEH $50.08
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- LXEH 63.64
- ANL 58.53
- Support Level
- LXEH $2.26
- ANL $1.65
- Resistance Level
- LXEH $2.69
- ANL $1.88
- Average True Range (ATR)
- LXEH 0.22
- ANL 0.11
- MACD
- LXEH 0.04
- ANL -0.00
- Stochastic Oscillator
- LXEH 73.20
- ANL 53.21
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.